If you would like to submit a blog post for consideration, please email email@example.com
[4 min read] Breast cancer drug may treat mucosal melanoma
A drug typically used to treat breast cancer may also be effective in treating mucosal melanoma.
There are no known risk factors for mucosal melanoma and the prognosis is very poor. Typical treatments for mucosal melanoma follow the same regime as for skin melanoma, but are not very effective. Less than 20 per cent of patients survive five years after diagnosis.
Now an international study – led by Melanoma Institute Australia and The University of Sydney – has uncovered genetic drivers for mucosal melanoma as well as potential treatments.
Utilising genome sequencing technology, researchers analysed samples of mucosal melanoma collected from around the world to learn more about the genetic abnormalities in the cancer.
The study identified that CDK4/6 – a drug inhibitor currently used to treat breast cancer – may be effective in some patients with mucosal melanoma.
This would have an immense impact on outcomes for patients diagnosed with the disease.
The next step is to develop a clinical trial to test classes of drugs and their effectiveness.
Source: Newell, F. et al. (18 July 2019.) Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications. Volume 10, Article number: 3163 (2019).
Interested in skin cancer medicine?
The HealthCert Professional Diploma programs offer foundation to advanced training in skin cancer medicine, skin cancer surgery or dermoscopy and provide an essential step towards subspecialisation. All programs are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The programs are delivered online and/or face-to-face across most major cities of Australia.